ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

4:00PM-5:30PM: Abstract Number: 2525

Comparing Patellar Tendon Characteristics Between Adults with and Without Knee Pain

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation

4:00PM-5:30PM: Abstract Number: 2518

Could the Adenosine Pathway Identify Cases with a Progressive Fibrosing Phenotype Between Patients with Autoimmune Interstitial Lung Disease? An Initial Approach

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

4:00PM-5:30PM: Abstract Number: 2528

Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science

4:00PM-5:30PM: Abstract Number: 2503

Cytokines Regulate the Fibrotic Response of Growth Factors in Joint Fibroblast-like Synoviocytes

Abstracts: Cytokines & Cell Trafficking

4:00PM-5:30PM: Abstract Number: 2522

Diabetes Mellitus Impacts Primary Total Hip Arthroplasty Outcomes: A National Cohort Study

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation

4:00PM-5:30PM: Abstract Number: 2541

Differential Responses to Initial Treatment Strategies for Rheumatoid Arthritis Among Those with Lower Body Mass and Adiposity

Abstracts: RA – Treatments III: Predictors of Response & Tapering

4:00PM-5:30PM: Abstract Number: 2505

Discovery of First-in-Class IRAK4 Scaffolding Inhibitors for the Treatment of Inflammatory Disorders

Abstracts: Cytokines & Cell Trafficking

4:00PM-5:30PM: Abstract Number: 2536

DMARD Adherence During the COVID-19 Pandemic and Association with Risk of COVID-19 Infection

Abstracts: Patient Outcomes, Preferences, & Attitudes II: Patient Experience

4:00PM-5:30PM: Abstract Number: 2549

Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients with Radiographic Axial Spondyloarthritis; A Post-hoc Analysis of a Placebo and Active Controlled RCT

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment III: AxSpA

4:00PM-5:30PM: Abstract Number: 2545

Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment III: AxSpA

4:00PM-5:30PM: Abstract Number: 2556

End-of-Life in Systemic Lupus Erythematosus Beset by Increased Flares and Higher Treatment Burden: Data from a Prospective Large Multinational Cohort

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Disease Activity

4:00PM-5:30PM: Abstract Number: 2520

Identification of Clinical Phenotypes in Sarcoidosis Using a Cluster Analysis

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

4:00PM-5:30PM: Abstract Number: 2562

Immune Checkpoint Inhibitors-Induced Large Vessel Vasculitis: Data from a Multicenter Study

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II: Clinical

4:00PM-5:30PM: Abstract Number: 2542

Impact of Concomitant Methotrexate on Disease Activity After Tapering Abatacept in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study

Abstracts: RA – Treatments III: Predictors of Response & Tapering

4:00PM-5:30PM: Abstract Number: 2537

Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs

Abstracts: Patient Outcomes, Preferences, & Attitudes II: Patient Experience

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].